Hjem › Glioblastom › North Carolina › Durham
Kliniske studier for Glioblastom i Durham, NC
20 studier for Glioblastom søker deltakere på steder i og rundt Durham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
RekruttererFase 3
- University of North Carolina, Chapel Hill · 10 mi unna
Targeted Pediatric High-Grade Glioma Therapy
RekruttererObservasjonsstudie
- Duke University Health System, Durham
Study of Olutasidenib and Temozolomide in HGG
RekruttererFase 2
- Duke University Health System, Durham
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekruttererFase 3
- Duke Cancer Institute, Durham
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
RekruttererFase 1
- Duke University Medical Center, Durham
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
RekruttererFase 2
- Duke University Medical Center, Durham
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RekruttererFase 2
- Duke University, Durham
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
RekruttererFase 2
- Duke University, Durham
Lerapolturev (PVSRIPO) in GBM
RekruttererFase 2
- Duke University Medical Center, Durham
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RekruttererFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RekruttererTidlig fase 1Frivillige helsepersonell ønskes velkommen
- Duke University Health System, Durham
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
RekruttererFase 1
- Duke University Medical Center, Durham
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RekruttererFase 2
- Duke University Health System, Durham
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RekruttererFase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Key Longitudinal Associations With Risk and Glioblastoma Outcomes
RekruttererObservasjonsstudie
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi unna
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
RekruttererFase 1
- Duke University Medical Center, Durham
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
RekruttererFase 1/2
- Duke University Medical Center, Durham
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RekruttererFase 2
- University of North Carolina, Chapel Hill · 10 mi unna
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RekruttererFase 1
- Duke University, Durham
Glioblastom-studier i andre byer
- New York City, NY30 studier
- Boston, MA28 studier
- Houston, TX26 studier
- Los Angeles, CA24 studier
- San Francisco, CA17 studier
- Chicago, IL15 studier
- Washington, DC15 studier
- Columbus, OH14 studier
- Miami, FL14 studier
- Rochester, MN13 studier
- Jacksonville, FL13 studier
- Aurora, CO12 studier
Andre studier i Durham
- Brystkreft64 studier
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft39 studier
- Multipelt myelom37 studier
- Akut myelogen leukemi33 studier
- Metastatisk kreft33 studier
- Prostatakreft32 studier
- Lungekreft32 studier
- Kolorektal kreft28 studier
- Eggstokkreft27 studier
- Kronisk lymfatisk leukemi27 studier
- Hjertesvikt26 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.